Skip to content

Video Journal: One Woman Shares Her Cross-Linking Journey

Tags: About iLink

Bekah was diagnosed with keratoconus when she was 36 after she failed her vision exam at the DMV. Similar to others who are diagnosed with this condition, Bekah didn’t know anyone who was living with keratoconus and began a quick study of the condition and her potential treatment options. Like many people and their families who are living with keratoconus, Bekah relied on advice from her doctors and online research to help determine what treatment path she should follow. She ultimately decided on FDA approved cross-linking. In July 2018, Bekah video blogged her cross-linking journey to share with other keratoconus patients and their families she had connected with along her way. In this powerful video series, Bekah covers her experience from nerves leading up to procedure day through her recovery. Check out the below videos to hear how her journey went in Bekah’s own words.

Pre-Cxl Part 1 of 2

Pre-Cxl Part 2 of 2

Day After CXL

48 Hours Post-CXL

5 Days Post-CXL

10 Days Post-CXL

The results described on this site are based on data collected regarding short- and intermediate-term efficacy of treatment. Individual results are not guaranteed and may vary.
Find a Doctor

Important Safety Information

Ulcerative keratitis, a potentially serious eye infection, can occur. Your doctor should monitor defects in the outermost corneal layer of the eye for resolution.

The most common ocular side effect is haze. Other ocular side effects include inflammation, fine white lines, dry eye, disruption of surface cells, eye pain, light sensitivity, reduced sharpness of vision, and blurred vision. The risk information provided here is not comprehensive. To learn more, talk to your healthcare provider.

Go to Prescribing Info to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program, or call 1-800-FDA-1088.

Approved Uses

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are used with the KXL® System in corneal cross-linking to treat eyes in which the cornea, the clear dome shaped surface that covers the front of the eye, has been weakened from the progression of the disease keratoconus or following refractive surgery, a method for correcting or improving your vision.

Tell your healthcare provider if you are pregnant or plan to become pregnant.